Elevance Health, Inc. (BMV:ELV)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.47T -20.5% |
| Revenue (ttm) | 3.61T +9.4% |
| Net Income | 94.52B -11.4% |
| EPS | 423.96 -8.1% |
| Shares Out | n/a |
| PE Ratio | 15.54 |
| Forward PE | 15.05 |
| Dividend | 126.14 (1.91%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | n/a |
| Average Volume | 1,318 |
| Open | 6,592.00 |
| Previous Close | 6,592.00 |
| Day's Range | 6,592.00 - 6,592.00 |
| 52-Week Range | 4,960.00 - 7,446.44 |
| Beta | n/a |
| RSI | 59.04 |
| Earnings Date | Jul 15, 2026 |
About Elevance Health
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, a... [Read more]
Financial Performance
In 2025, Elevance Health's revenue was $199.13 billion, an increase of 12.62% compared to the previous year's $176.81 billion. Earnings were $5.66 billion, a decrease of -5.32%.
Financial numbers in USD Financial StatementsNews
Elevance Health price target raised to $460 from $400 at UBS
UBS raised the firm’s price target on Elevance Health (ELV) to $460 from $400 and keeps a Buy rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected…
Elevance Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Elevance Health (ELV) to Buy from Hold with a price target of $498, up from $363. The firm upgraded three managed care names citing a stabilizing managed…
Elevance Health price target raised to $435 from $385 at Mizuho
Mizuho raised the firm’s price target on Elevance Health (ELV) to $435 from $385 and keeps an Outperform rating on the shares. The firm views the Q1 reports in the…
Elevance Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Elevance Health (ELV) to Buy from Hold with a price target of $498, up from $363.
Elevance Health added to ‘Tactical Outperform’ list at Evercore ISI
Evercore ISI is adding Elevance Health (ELV) to the firm’s “Tactical Outperform” list for Q2, telling investors that the company is poised for “significant upside EPS this year” if current…
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
Elevance Health Transcript: AGM 2026
The meeting covered strong financial growth, board updates, and strategic initiatives in efficiency, digital transformation, and value-based care. All board proposals passed, while a shareholder proposal on political contributions failed.
Health Insurers Performing Better But There's Potential Trouble Ahead
Health insurance companies including UnitedHealthcare, CVS Health's Aetna, Centene and Blue Cross and Blue Shield plans owned by Elevance Health are seeing lower costs from patients submitting claims.
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But a...
Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care
INDIANAPOLIS--(BUSINESS WIRE)--Despite growing awareness, mental health concerns remain difficult to navigate and often lead to avoidable crises, costly emergency room visits, and long-term strain on ...
Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider ...
Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
INDIANAPOLIS--(BUSINESS WIRE)--As small businesses continue to face rising healthcare costs, Elevance Health's affiliated health plans are delivering solutions that help employers offer competitive be...
Elevance Health upgraded at BofA on Medicaid margins trough
As previously reported, BofA analyst Kevin Fischbeck upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $405, citing increased confidence that Medicaid margins…
Elevance Health upgraded to Buy from Neutral at BofA
BofA analyst Kevin Fischbeck upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $425.
Elevance Health upgraded to Buy from Neutral at BofA
BofA upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $405.
Elevance Health price target raised to $411 from $397 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Elevance Health (ELV) to $411 from $397 and keeps an Overweight rating on the shares. The firm updated the company’s…
Elevance Health price target raised to $399 from $396 at Guggenheim
Guggenheim raised the firm’s price target on Elevance Health (ELV) to $399 from $396 and keeps a Buy rating on the shares. Q1 upside was “largely telegraphed, but nonetheless a…
Elevance Health price target raised to $408 from $393 at Barclays
Barclays raised the firm’s price target on Elevance Health (ELV) to $408 from $393 and keeps an Overweight rating on the shares post the Q1 report. The firm sys its…
Elevance Health price target raised to $364 from $357 at Leerink
Leerink raised the firm’s price target on Elevance Health (ELV) to $364 from $357 and keeps a Market Perform rating on the shares. Following Q1 results, the firm’s 2026 adjusted…
Elevance Health price target raised to $331 from $317 at Baird
Baird raised the firm’s price target on Elevance Health (ELV) to $331 from $317 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results…
Elevance Health Earnings Call Transcript: Q1 2026
Q1 results exceeded expectations with strong EPS and revenue growth, driven by ACA seasonality, cost management, and non-recurring investment income. Full-year EPS guidance was raised, and strategic investments in AI and Carelon are supporting operational improvements and long-term growth.
Elevance Health Earnings release: Q1 2026
Elevance Health released its Q1 2026 earnings on April 22, 2026, summarizing the period's financial results.
Elevance Health Slides: Q1 2026
Elevance Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
Elevance Health Quarterly report: Q1 2026
Elevance Health has published its Q1 2026 quarterly earnings report on April 22, 2026.
Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs
Elevance Health Wednesday reported nearly $1.8 billion in first quarter net income as costs continued to be a drag on earnings of the nation's second-largest health insurance company.